Multiple endocrine neoplasia type 2 screening

Jump to navigation Jump to search

Multiple endocrine neoplasia type 2 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 2 from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Criteria

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Multiple endocrine neoplasia type 2 screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 2 screening

CDC on Multiple endocrine neoplasia type 2 screening

Multiple endocrine neoplasia type 2 screening in the news

Blogs on Multiple endocrine neoplasia type 2 screening

Directions to Hospitals Treating Multiple endocrine neoplasia type 2

Risk calculators and risk factors for Multiple endocrine neoplasia type 2 screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

According to the American Society of Clinical Oncology, screening for multiple endocrine neoplasia type 2 by RET gene testing is recommended for children with increased risk of multiple endocrine neoplasia type 2.

Screening

  • The DNA-based testing of the c-RET gene is recommended for children with increased risk of multiple endocrine neoplasia type 2.[1][2][3][4]
  • The DNA-based testing of the c-RET gene can be easily performed on a blood sample at any age.
  • The DNA-based testing of the c-RET gene offers the opportunity for early identification of the c-RET germline mutations, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant gene carriers makes possible the prevention and cure of medullary thyroid cancer, by performing a prophylactic thyroidectomy before the clinical expression of the tumor.
  • The DNA-based testing of the c-RET gene test is also of importance to detect and thus, to reduce the risk of an unsuspected pheochromocytoma.
  • Screening for multiple endocrine neoplasia type 2 include the following tests:


Screening for multiple endocrine neoplasia type 2
The DNA-based testing of the c-RET gene
▸ Children with c-RET codon 609, 768, 790, 791, 804 and 891 mutations are more prone to less aggressive and slowly growing medullary thyroid cancer and a periodic pentagastrin-stimulated test with thyroidectomy, at the first abnormal test result, has been recommended.
▸ Individuals with c-RET codon 609, 611, 618, 620, 630, 634, 790, V804L, 883, 918 or 922 mutations should be routinely screened for pheochromocytoma by annual determinations of fractionated urinary and free plasma metanephrines and catecholamines.
  • Screening of the pregnant woman with an increased risk of multiple endocrine neoplasia type 2 is recommended to identify mutations in the RET gene of the offspring.

References

  1. Yip, Linwah (2003). "Multiple Endocrine Neoplasia Type 2". Archives of Surgery. 138 (4): 409. doi:10.1001/archsurg.138.4.409. ISSN 0004-0010.
  2. Multiple endocrine neoplasia type2. Orphanet (30.10.2015). http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=653 Accessed on October, 30, 2015
  3. Marini, Francesca; Falchetti, Alberto; Del Monte, Francesca; Carbonell Sala, Silvia; Tognarini, Isabella; Luzi, Ettore; Brandi, Maria (2006). Orphanet Journal of Rare Diseases. 1 (1): 45. doi:10.1186/1750-1172-1-45. ISSN 1750-1172. Missing or empty |title= (help)
  4. Friedhelm Raue & Karin Frank-Raue (2012). "Genotype-phenotype correlation in multiple endocrine neoplasia type 2". Clinics (Sao Paulo, Brazil). 67 Suppl 1: 69–75. doi:10.6061/clinics/2012(sup01)13. PMID 22584709.


Template:WikiDoc Sources